Michael W. Bolt

674 total citations
16 papers, 419 citations indexed

About

Michael W. Bolt is a scholar working on Molecular Biology, Hematology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Michael W. Bolt has authored 16 papers receiving a total of 419 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Hematology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Michael W. Bolt's work include Blood Coagulation and Thrombosis Mechanisms (5 papers), Hemophilia Treatment and Research (3 papers) and Blood properties and coagulation (2 papers). Michael W. Bolt is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (5 papers), Hemophilia Treatment and Research (3 papers) and Blood properties and coagulation (2 papers). Michael W. Bolt collaborates with scholars based in United States, Canada and United Kingdom. Michael W. Bolt's co-authors include William J. Racz, James F. Brien, Thomas E. Massey, Thomas W. Jones, Timothy K. Hart, Maggie Liu, Thomas M. Monticello, Donna M. Dambach, David M. Potter and Douglas A. Keller and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS Biology.

In The Last Decade

Michael W. Bolt

15 papers receiving 400 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael W. Bolt United States	9	162	67	54	47	46	16	419
Magali Guffroy United States	12	136 0.8×	123 1.8×	13 0.2×	32 0.7×	37 0.8×	27	640
Tamio Fukushima Japan	13	171 1.1×	74 1.1×	26 0.5×	39 0.8×	12 0.3×	29	451
Evangelos Hytopoulos United States	10	212 1.3×	94 1.4×	88 1.6×	55 1.2×	84 1.8×	21	452
Raja S. Mangipudy United States	15	182 1.1×	61 0.9×	14 0.3×	77 1.6×	19 0.4×	28	641
Susan Kadner United States	18	214 1.3×	139 2.1×	28 0.5×	35 0.7×	21 0.5×	35	716
Xiling Jiang United States	10	98 0.6×	90 1.3×	13 0.2×	62 1.3×	114 2.5×	18	455
Yasuhiro Sato Japan	10	102 0.6×	15 0.2×	8 0.1×	75 1.6×	20 0.4×	27	510
Jon Hill United States	10	315 1.9×	58 0.9×	38 0.7×	31 0.7×	23 0.5×	14	585
Shao-Ming Shen China	13	410 2.5×	61 0.9×	10 0.2×	43 0.9×	70 1.5×	24	686
Pamela DeLuca United States	8	354 2.2×	60 0.9×	28 0.5×	35 0.7×	13 0.3×	10	574

Countries citing papers authored by Michael W. Bolt

Since Specialization

Citations

This map shows the geographic impact of Michael W. Bolt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael W. Bolt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael W. Bolt more than expected).

Fields of papers citing papers by Michael W. Bolt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael W. Bolt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael W. Bolt. The network helps show where Michael W. Bolt may publish in the future.

Co-authorship network of co-authors of Michael W. Bolt

This figure shows the co-authorship network connecting the top 25 collaborators of Michael W. Bolt. A scholar is included among the top collaborators of Michael W. Bolt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael W. Bolt. Michael W. Bolt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Hwang, Seo‐Kyoung, et al.. (2023). Sex-related differences in retinal function in Wistar rats: implications for toxicity and safety studies. SHILAP Revista de lepidopterología. 5. 1176665–1176665. 3 indexed citations

Bolt, Michael W., et al.. (2021). Development challenges associated with rAAV-based gene therapies. The Journal of Toxicological Sciences. 46(2). 57–68. 25 indexed citations

Bolt, Michael W., Laurence O. Whiteley, Jessica Lynch, et al.. (2020). Nonclinical Studies that Support Viral Vector-Delivered Gene Therapies: An EFPIA Gene Therapy Working Group Perspective. Molecular Therapy — Methods & Clinical Development. 19. 89–98. 5 indexed citations

Parng, Chuenlei, et al.. (2019). Induction and Impact of Anti-Drug Responses Elicited by a Human Recombinant Coagulation Factor FXaI16L in Preclinical Species. The AAPS Journal. 21(3). 52–52. 3 indexed citations

Bolt, Michael W., et al.. (2019). Evaluation of biomarkers for monitoring thrombogenic potential of FXaI16L. Blood Coagulation & Fibrinolysis. 31(1). 16–28.

McClellan, Joseph E., et al.. (2019). The ‘totality-of-the-evidence’ approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product. Therapeutic Advances in Gastroenterology. 12. 3973041399–3973041399. 12 indexed citations

Lintner, Nathanael G., Kim F. McClure, Donna N. Petersen, et al.. (2017). Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain. PLoS Biology. 15(3). e2001882–e2001882. 94 indexed citations

Parng, Chuenlei, Jianqing Chen, Michael W. Bolt, et al.. (2017). Preclinical Pharmacokinetics, Pharmacodynamics, Tissue Distribution, and Interspecies Scaling of Recombinant Human Coagulation Factor Xa I16L. Journal of Pharmaceutical Sciences. 106(8). 2136–2143. 8 indexed citations

Monticello, Thomas M., Thomas W. Jones, Donna M. Dambach, et al.. (2017). Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: The IQ consortium nonclinical to clinical translational database. Toxicology and Applied Pharmacology. 334. 100–109. 106 indexed citations

10.

Johnson, Theodore R., Ahmed Shoieb, Hugh D. Conlon, et al.. (2016). Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab). Advances in Therapy. 33(11). 1964–1982. 31 indexed citations

11.

David, Tovo, Lauren K. Ely, Isaac J. Rondon, et al.. (2016). Factor XIa–specific IgG and a reversal agent to probe factor XI function in thrombosis and hemostasis. Science Translational Medicine. 8(353). 353ra112–353ra112. 39 indexed citations

12.

Bolt, Michael W., et al.. (2014). Evaluation of Potential Safety Biomarkers for Monitoring Thrombogenic Potential of FXaI16L. Blood. 124(21). 4237–4237. 3 indexed citations

13.

Bolt, Michael W., William J. Racz, James F. Brien, & Thomas E. Massey. (2001). Effects of vitamin E on cytotoxicity of amiodarone and N-desethylamiodarone in isolated hamster lung cells. Toxicology. 166(3). 109–118. 19 indexed citations

14.

Bolt, Michael W., Jeffrey W. Card, William J. Racz, James F. Brien, & Thomas E. Massey. (2001). Disruption of Mitochondrial Function and Cellular ATP Levels by Amiodarone and N-Desethylamiodarone in Initiation of Amiodarone-Induced Pulmonary Cytotoxicity. Journal of Pharmacology and Experimental Therapeutics. 298(3). 1280–1289. 56 indexed citations

15.

Bolt, Michael W., William J. Racz, James F. Brien, Tammy Μ. Bray, & Thomas E. Massey. (1998). Differential susceptibilities of isolated hamster lung cell types to amiodarone toxicity. Canadian Journal of Physiology and Pharmacology. 76(7-8). 721–727. 7 indexed citations

16.

Bolt, Michael W., et al.. (1996). Modulation of aflatoxin B 1 biotransformation by β -naphthoflavone in isolated rabbit lung cells. Archives of Toxicology. 71(1-2). 72–79. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact